Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist and a benchmark compound in metabolic research — studied for combined effects on glucose-dependent insulin secretion, appetite signaling, and body-weight regulation.

What makes it distinct
By co-activating two incretin receptors rather than one (GLP-1 alone), tirzepatide is the standard against which both single-receptor agonists and next-generation triple agonists are compared. It sits one step beyond GLP-1 mono-agonists on the receptor-engagement spectrum, and one step below the triple agonist GLP-3 RT (Retatrutide).

Research context
Tirzepatide is an approved pharmaceutical (developed and patented by Eli Lilly), which is why it functions as a reference standard rather than a novel research peptide. Its pharmacology is defined by an extensive human trial base — the SURPASS (diabetes) and SURMOUNT (obesity) programs — cited in the overview below. This research-grade material is supplied for in-vitro and laboratory study only. Full mechanism and literature: read our Tirzepatide Research Overview » and compare it with the triple-agonist GLP-3 RT (Retatrutide) »

Purity & testing
– ≥99% purity (this lot: 99.90% by HPLC)
– Lyophilized powder for laboratory reconstitution
– Batch-specific Certificate of Analysis — HPLC + mass spec, heavy metals, sterility, endotoxin
– ISO/IEC 17025-accredited third-party testing → View the COA »

Laboratory handling
Store lyophilized material cold and protected from light (long-term at −20 °C). After reconstitution, refrigerate at 2–8 °C and use within your protocol window. Confirm identity and purity against the batch COA before use.

Research FAQ
How does tirzepatide differ from semaglutide? Semaglutide is a GLP-1 mono-agonist; tirzepatide co-activates both the GIP and GLP-1 receptors.
How does it differ from GLP-3 RT (Retatrutide)? Tirzepatide engages two receptors (GIP/GLP-1); GLP-3 RT adds a third (glucagon), making it a triple agonist.

For laboratory and research use only. Not for human or veterinary consumption, and not for diagnostic or therapeutic use. Tirzepatide is a patented, approved pharmaceutical; this material is a research-grade reference standard. These statements have not been evaluated by the FDA.